FLGT
Fulgent Genetics, Inc.
FLGT has a slight edge over NVO overall, supported by stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
FLGT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Strong |
FLGT's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
FLGT PE Valuation
FLGT has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
FLGT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect FLGT's losses to grow, with revenue growing.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
NVO has the edge over FLGT on the outlook, with more favorable earnings expectations.
FLGT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.10 | -$1.71 |
| Q2 2026 | -$2.83 | -$1.17 |
| Q1 2026 | -$2.40 | -$1.07 |
| Q4 2025 | -$1.97 | -$0.56 |
| Q3 2025 | -$1.39 | +$4.12 |
| Q2 2025 | -$1.66 | +$3.81 |
| Q1 2025 | -$1.33 | +$4.23 |
| Q4 2024 | -$1.41 | +$4.22 |
FLGT lost $3.10 per share over the past year, and its loss has widened in each of the last four quarters.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over FLGT on earnings quality, reporting a profit while its opponent remains loss making.
FLGT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $90.4M | +7.5% |
| Q2 2026 | $85.4M | +4.4% |
| Q1 2026 | $71.1M | -3.2% |
| Q4 2025 | $83.3M | +9.3% |
| Q3 2025 | $84.1M | +17% |
| Q2 2025 | $81.8M | +15% |
| Q1 2025 | $73.5M | +14% |
| Q4 2024 | $76.2M | +8.1% |
FLGT's revenue is recovering but still below its 2021 peak: $90M last quarter, up 7.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -25% | -6.7 points |
| Q2 2026 | -42% | -18 points |
| Q1 2026 | -49% | -22 points |
| Q4 2025 | -43% | -22 points |
| Q3 2025 | -18% | +5.5 points |
| Q2 2025 | -24% | +2.5 points |
| Q1 2025 | -27% | +6.8 points |
| Q4 2024 | -21% | +193 points |
FLGT's operating margin was −25% last quarter, down 6.7 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over FLGT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over FLGT on profitability, with a higher operating margin.
FLGT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $107.4M | +2025% |
| Q2 2026 | -$27.6M | +$9.4M |
| Q1 2026 | $1.9M | +$11M |
| Q4 2025 | -$83.1M | -491% |
| Q3 2025 | $5.1M | +$40.1M |
| Q2 2025 | -$37M | -$28.3M |
| Q1 2025 | -$9.1M | -385% |
| Q4 2024 | $21.2M | +80% |
FLGT's free cash flow was −$1M over the past year, against −$20M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over FLGT on cash generation, producing positive trailing cash flow while its opponent burns cash.
FLGT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -343K shares |
| 1 year | -10% | -3.1M shares |
| 3 years | -7.8% | -2.4M shares |
| 5 years | -11% | -3.5M shares |
| Available history | +48% | +9M shares |
FLGT has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $251,000 |
| Q2 2026 | $23.8M |
| Q1 2026 | $40.1M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.2M |
| Q1 2025 | $8.7M |
| Q4 2024 | — |
FLGT spent $64M buying back its own shares over the past year, about six times what it spent the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
FLGT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -0.4x | Net Cash |
| Q3 2022 | -0.4x | Net Cash |
| Q2 2022 | -0.2x | Net Cash |
| Q1 2022 | -0.6x | Net Cash |
| Q4 2021 | -0.2x | Net Cash |
| Q3 2021 | -0.3x | Net Cash |
| Q2 2021 | -0.1x | Net Cash |
| Q1 2021 | -0.3x | Net Cash |
FLGT has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
FLGT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.9 | Neutral |
| Stochastic | 79.5 | Neutral |
FLGT's weekly RSI is 65 (neutral) and its Stochastic is 79 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
FLGT PE vs Healthcare Sector
| Metric | FLGT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
FLGT has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
FLGT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.8 | 14% above |
| 20 week MA | $20.6 | 21% above |
| 50 week MA | $20.5 | 22% above |
| 100 week MA | $20.4 | 22% above |
| 200 week MA | $23.7 | 4.9% above |
FLGT has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
FLGT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.2 | $45.8 | +246% |
| 2021 | $45.8 | $100.2 | +119% |
| 2022 | $100.2 | $30.3 | -70% |
| 2023 | $30.3 | $28.9 | -4.7% |
| 2024 | $28.9 | $18.4 | -36% |
| 2025 | $18.4 | $26.7 | +45% |
| 2026 YTD | $26.7 | $24.9 | -7% |
FLGT has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.